According to the latest report by IMARC Group, titled, “Anti-Rheumatics Market Growth: Global Industry Trends, Share, Size, Opportunity and Forecast 2022-2027“, The global anti-rheumatics market reached a value of US$ 61.1 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 72.1 Billion by 2027, exhibiting at a CAGR of 2.74% during 2022-2027.
Anti-rheumatics refer to the medications that are used for treating rheumatoid arthritis, a chronic inflammatory medical condition. Anti-rheumatic drugs are commonly prescribed by healthcare professionals to halt the disease progression. Apart from this, it is also utilized to treat inflammatory myositis, bowel diseases, and cancer.
Get a PDF Sample for more detailed market insights: https://www.imarcgroup.com/anti-rheumatics-market/requestsample
The global market is majorly driven by the increasing incidences of rheumatoid arthritis across the globe. Along with this, the widespread adoption of biosimilars and novel biologic therapies among the masses is also contributing to the market growth. Moreover, the rising prevalence of acute and chronic medical conditions, such as systemic sclerosis, systematic lupus erythematosus, and Sjogren syndrome, is providing a boost to the demand for anti-rheumatics across the globe. Other factors, including the increasing investments by public and private firms to upgrade the existing healthcare infrastructure and extensive research and development (R&D) activities conducted by key players, are driving the market growth further.
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
The competitive landscape of the industry has also been examined along with the profiles of the key players.
- AbbVie Inc. (ABBV)
- Amgen Inc.
- AstraZeneca plc
- Biogen Inc.
- Bristol-Myers Squibb Company
- Celltrion Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- Johnson & Johnsons
- Pfizer Inc.
- Sanofi SA.
The report has segmented the market on the basis of Type, Drug Class, Route of Drug Administration, Distribution Channel and Region.
Breakup by Type:
- Prescription-based Drugs
- Over-the-Counter Drugs
Breakup by Drug Class:
- Disease Modifying Anti-Rheumatics Drugs (DMARD’s)
- Nonsteroidal Anti-Inflammatory Drugs (NSAID’s)
- Uric Acid Drugs
Breakup by Route of Drug Administration:
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
Breakup by Region:
- North America
- Latin America
- Middle East and Africa
For more information about this report visit: https://www.imarcgroup.com/anti-rheumatics-market
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800